Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: dino who wrote (2828)	1/21/1998 7:37:00 PM
From: Riverlightning	Read Replies (1) \| Respond to of 3906

dino, The phone number with the solicitation is 1-800-433-1528. Chances are this is just for subscribing via credit card. I doubt if they will want to explain much even if they could since we are not subscribers.But, if you try act as if you don't know the name and are interested in subscribing and by the way are you guys still high on that Nevada drug company and why. Maybe then they will tell you more.

To: dino who wrote (2828)	1/21/1998 7:58:00 PM
From: M. Alexander	Read Replies (2) \| Respond to of 3906

In this month's Worth magazine, I finally got some idea of what Phase I, II, and III mean. The article is about Alan Carr the pres. of Hambrecht & Quist Capital Management and just states that he (Alan) feels that the three year biotech slide is over and a boom is eminent. But that's not the point. The point is that now I know what the general definition of these trials is and it isn't what I had expected. I thought that the divisions of phases were catagories for safety, efficacy and perhaps something else respectively. But according to Worth quoting Bear Stearns..Phase I examines how healthy volunteers react to a single onetime dose of a drug. Phase II studies how well the drug works on a small sample of patients with the condition in question. And Phase III tests a drug on a large population to confirm efficacy, gauge dosage, and discover long-term effects. There is no mention of nonhuman testing of any sort which I thought was odd but I would think that they would have people breaking down the doors to test a drug in this field. At least for the Phase I they could probably find unpaid volunteers. In fact I am sure that they can recieve many other unpaid volunteers also for the next two Phases which ought to help with the bill. Speaking of the bill, the Bear Stearns estimate is that Phase I takes one years to complete, $9 mil., and has a 38% failure rate. Phase II takes 1-3 years, $22 mil., and has a 40 % failure rate..all averages of course but has some place in the perspective of HVSF, especially I think with the $. Finally Phase III takes 1-4 years (which is why they want to combine the two, I imagine.), a healthy additional dose of $53 mil., and has a 45% failure rate. So it looks like HVSF's plan is rather aggresive hoping to tackle everything by this September, and money is a big issue. They are playing a very big game for big gains. And we are all footing a tiny portion of the bill when we purchase their shares or are holding the shareholder "seat" of whoever did initially purchase them. Intellectually we all know that of course but at least we can see how HVSF's expectations compare to the average biotech. It's no guarantee of anything but it's food for thought... M. Alexander